|
FDA Approves Lilly’s Once-Weekly Basal Insulin Onswik for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 1383
|
|
REACT Study Challenges How We Think About Cardiovascular Disease Prevention
|
Written by: J. Smith |
Hits: 178
|
|
FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 164
|
|
Why Context Matters in Diabetes Data Analytics
|
Written by: J. Smith |
Hits: 69
|
|
FDA Authorizes Abbott Libre Duo for Continuous Glucose and Ketone Monitoring
|
Written by: J. Smith |
Hits: 117
|
|
Awiqli, the First Once-Weekly Basal Insulin, Now Available in the US
|
Written by: J. Smith |
Hits: 244
|
|
Low Diabetes Medication Adherence Linked to Higher Cardiovascular Risk Over 10 Years
|
Written by: J. Smith |
Hits: 134
|
|
Novo Nordisk’s Ziltivekimab Fails to Reduce Cardiovascular Events in Phase 3 Trial
|
Written by: J. Smith |
Hits: 150
|
|
Retatrutide Delivers Major Weight Loss, but Real-World Success Will Depend on More Than Efficacy
|
Written by: J. Smith |
Hits: 131
|
|
Secret Shopper Study Raises Concerns About Online GLP-1 Prescribing
|
Written by: J. Smith |
Hits: 141
|
